logo
Plus   Neg
Share
Email

LafargeHolcim Q1 Net Sales, Recurring EBIT Down - Quick Facts

Cement giant LafargeHolcim (HCMLY.PK,HCMLF.PK) Thursday reported 11.2 percent in decline in sales and 14.1 percent decrease in recurring EBIT for the first quarter.

The Group's net sales for the quarter slid by 11.2 percent to 5.29 billion Swiss francs from last year's 5.96 billion francs. On LFL basis, sales were down 3.3 percent.

Recurring EBIT for the period was down by 14.1 percent to 262 million francs from 305 million francs, while it was down by 2.6 percent on LFL basis.

The Group also reported operating profit of 244 million francs for the quarter, lower than the year-ago's 288 million francs.

Looking ahead, LafargeHolcim said it is well-positioned to weather the COVID-19 pandemic crisis, but expects its impact in the second quarter. The company also added that the full impact of the crisis on its 2020 results cannot be assessed at this point.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT